Recovery of 157 COVID-19 Patients with Tailored Treatment Regime: A Single Centre Study at Dedicated COVID Hospital (DCH) in India

Background: The regimen in treatment of Covid 19 disease patients is quite variable, with wide range of outcomes. We present our successful recovery rates of COVID 19 disease patients with our tailored treatment based on comorbidity and clinical symptoms. Methodology: We retrospectively analysed 157 consecutive discharged patients with Covid‐19 from 20th March 2020 to 20th May 2020. They were admitted and treated at Pandit Bhimsen Joshi General Hospital. Results: The Gender distribution was 86(54.8 %) males and 71(45.2%) females. Mean length of hospital stay was 13 days. Among the total of 157 patients, 41(26.1%) had co-morbidities. Study results revealed that patients with comorbidities have three times (OR=2.92) higher risk of death compared with patients without any comorbidities. Diabetic patients have four times (OR = 4.1) higher risk of death compared with patients without any comorbidities. X-ray of patients showed 88% had no pulmonary involvement, 6.3% Bilateral Alveolar shadow, 3.18% unilateral alveolar shadow and 2.54 % unilateral consolidation. Conclusion: Generally focus is on fever as primary symptom, our majority patients were asymptomatic. Three tailor made regimens approach for asymptomatic, mild cases and moderate to severe Covid 19 cases yielded in good recovery rate. Study results revealed that patients with comorbidities have three times (OR=2.92) higher risk of death compared with patients without any comorbidities. Diabetic patients have four times (OR=4.1) higher risk of death compared with patients without any comorbidities. Funding Statement: None. Declaration of Interests: The authors declare no conflict of interest. All authors certify that they have no affiliations with or involvement in any organizations or entities with a financial interest beyond their full-time employment. Ethics Approval Statement: This study was approved by the Bhaktivedanta Hospital Ethics Committee for Bio-Medical and Health Research.